Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Ionis Pharmaceuticals (IONS) Stock Price & Analysis

1,663 Followers

IONS Stock Chart & Stats

$39.42$0.62(1.60%)
At close: 4:00 PM EST
$40$50$60Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$38.53 - $40.00
52-Week Range
$38.31 - $86.74
Previous Close
$38.80
Volume
N/A
Average Volume (3M)
2.83M
Market Cap
$6.55B
Enterprise Value
$13.25B
Total Cash (Recent Filing)
$2.05B
Total Debt (Recent Filing)
$2.42B
Price to Earnings (P/E)
―
Beta
0.98
Next Earnings
Nov 09, 2026 (Est.)
EPS Estimate
-1.23
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

RNA Platform And Product Expansion

Recent regulatory approvals validate Ionis’s RNA-targeted technology across multiple serious diseases and expand its commercial base. ZANVASTRO adds an independent neurology launch, while HIBSAGO strengthens partnered economics through potential milestones and royalties, supporting a broader product platform over time.

Commercial Revenue Growth

Underlying revenue growth is improving as commercial products and partnered programs contribute more meaningfully. DAWNZERA adoption, TRYNGOLZA’s expected second-half recovery, and continued R&D revenue provide multiple sources of expansion rather than relying on a single product or transaction.

Partnered Pipeline Strength

Positive late-stage data for sefaxersen demonstrates continued clinical productivity from Ionis’s antisense platform and partnership model. The program could generate future regulatory and sales milestones plus tiered royalties, while reinforcing Ionis’s position in RNA-based therapies for major unmet needs.

Bears Say

Persistent Losses And Cash Burn

Persistent cash consumption means Ionis is not yet funding its operations internally, despite very high gross margins. Ongoing investment in launches and development can sustain the burn, while the projected 2026 operating loss of $425M–$475M delays durable self-funded profitability.

Elevated Financial Leverage

High leverage combined with continuing losses reduces financial flexibility and increases the importance of maintaining substantial liquidity. Debt obligations can constrain capital allocation for pipeline development or commercialization, making the balance sheet a continuing risk while cash-flow breakeven remains several years away.

Clinical And Partner-outcome Risk

The pelacarsen failure shows that strong biomarker reductions may not translate into clinical outcomes, creating uncertainty around partnered pipeline value. Similar readout risk can affect future milestones, royalties, and the company’s ability to reach its 2028 cash-flow breakeven target.

Ionis Pharmaceuticals News

IONS FAQ

What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $38.31 and its highest was $86.74 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $6.55B.
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s next earnings report is estimated for Nov 09, 2026 (not yet confirmed), which is in 1 day.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Jul 29, 2026. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$1.089 by $0.399.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -1.23.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 166,184,330 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.69 in its last earnings report, beating expectations of -$1.089. Following the earnings report the stock price went down -2.278%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Hedge funds hold Ionis Pharmaceuticals shares: the largest hedge-fund position in Ionis Pharmaceuticals is 71,885,365 shares, and hedge funds increased their holdings by 345.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology